CFTR, bicarbonate, and the pathophysiology of cystic fibrosis

Pediatric Pulmonology

Volumn 50, Issue , 2015, Pages S24-S30

  Borowitz, Drucy ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

cystic fibrosis (CF)

Indexed keywords

BICARBONATE; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; MUCIN; CFTR PROTEIN, HUMAN; ION;

BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; CYSTIC FIBROSIS; DYSBIOSIS; GENE MUTATION; HUMAN; ION TRANSPORT; NONHUMAN; PANCREAS INSUFFICIENCY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM; REVIEW; SECRETION (PROCESS); STAPHYLOCOCCUS AUREUS; STOMACH ACID; ANIMAL; BODY FLUID; EPITHELIUM; GENETICS; METABOLISM; PH;

ANIMALS; BICARBONATES; BODY FLUIDS; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIUM; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; IONS; MUCINS;

EID: 84941049266     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23247     Document Type: Review

References (48)

1. Buman J, Quinton PM,. Lactate and bicarbonate uptake in the sweat duct of cystic fibrosis and normal subjects. Pediatr Res 1987; 21: 79-82.
2. Kim D, Liao J, Hanrahan JW,. The buffer capacity of airway epithelial secretions. Front Physiol 2014; 5: 188. doi: 10.3389
3. Bridges RJ,. Mechanisms of bicarbonate secretions: lessons from the airways. Cold Spring Harb Perspect Med 2012; 1-12.
4. Shamsuddin AK, Quinton PM,. Native small airways secrete bicarbonate. Am J Respir Cell Mol Biol 2014; 50: 796-804.
5. Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MH, Ramachandran S, Moninger TO, Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M, Bánfi B, Horswill AR, Stoltz DA, McCray PB, Jr, Welsh MJ, Zabner J,. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012; 487: 109-113.
6. Abou Alaiwa MH, Beer AM, Pezzulo AA, Launspach JL, Horan RA, Stoltz DA, Starner TD, Welsh MJ, Zabner J,. Neonates with cystic fibrosis have a reduced nasal liquid pH; a small pilot study. J Cyst Fibros 2014; 13: 373-377.
7. Tarran R,. PH-dependent mucosal dehydration. Pediatr Pulmonol 2014; 38: 121-122.
8. Althaus M,. ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art. Curr Mol Pharmacol 2013; 6: 3-12.
9. Garland AL, Walton WG, Coakley RD, Tan CD, Gilmore RC, Hobbs CA, Tripathy A, Clunes LA, Bencharit S, Stutts MJ, Betts L, Redinbo MR, Tarran R,. Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways. Proc Natl Acad Sci USA 2013; 110: 15973-15978.
10. Novak I, Wang J, Henriksen KL, Haanes KA, Krabbe S, Nitschke R, Hede SE,. Pancreatic bicarbonate secretion involves two proton pumps. J Biol Chem 2011; 286: 280-289.
11. Shcheynikov N, Wang Y, Park M, Ko SBH, Dorwart M, Naruse S, Thomas PJ, Muallem S,. Coupling modes and stoichiometry of Cl-/HCO3-exchange by slc26a3 and slc26a6. J Gen Physiol 2006; 127: 511-524.
12. Song Y, Yamamoto A, Steward MC, Ko SB, Stewart AK, Soleimani M, Liu BC, Kondo T, Jin CX, Ishiguro H,. Deletion of Slc26a6 alters the stoichiometry of apical Cl-/HCO-3 exchange in mouse pancreatic duct. Am J Physiol Cell Physiol. 2012; 303: C815-C824.
13. Park HW, Nam JH, Kim JY, Namkung W, Yoon JS, Lee JS, Kim KS, Venglovecz V, Gray MA, Kim KH, Lee MG,. Dynamic regulation of CFTR bicarbonate permeability by [Cl-]i and its role in pancreatic bicarbonate secretion. Gastroenterol 2010; 139: 620-631.
14. LaRusch J, Jung J, General IJ, Lewis MD, Park HW, Brand RE, Gelrud A, Anderson MA, Banks PA, Conwell D, et al., Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. PLoS Genet 2014; 10: e1004376.
15. Li W, Soave D, Miller MR, Keenan K, Lin F, Gong J, Chiang T, Stephenson AL, Durie P, Rommens J, Sun L, Strug LJ,. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum Genet 2014; 133: 151-161.
16. McClean P, Weaver LT,. Ontogeny of pancreatic exocrine function. Arch Dis Child 1993; 68: 62-65.
17. Nutton V,. Hippocratic theories. Ancient Medicine, 2nd edition. New York, NY: Routledge; 2013. pp 72-86.
18. Gustafsson JK, Ermund A, Ambort D, Johansson ME, Nilsson HE, Thorell K, Hebert H, Sjövall H, Hansson GC,. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. J Exp Med 2012; 209: 1263-1272.
19. Quinton PM,. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008; 372: 415-417.
20. Garcia MAS, Yang N, Quinton PM,. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest. 2009; 119: 2613-2622.
21. Cooper JL, Quinton PM, Ballard ST,. Mucociliary transport in porcine trachea: differential effects of inhibiting chloride and bicarbonate secretion. Am J Physiol Lung Cell Mol Physiol 2013; 304: L184-L190.
22. Birket SE, Chu KK, Liu L, Houser GH, Diephuis BJ, Wilsterman EJ, Dierksen G, Mazur M, Shastry S, Li Y, Watson JD, Smith AT, Schuster BS, Hanes J, Grizzle WE, Sorscher EJ, Tearney GJ, Rowe SM,. A functional anatomic defect of the cystic fibrosis airway. Am J Respir Crit Care Med 2015; 190: 421-432.
23. Yang N, Garcia MA, Quinton PM,. Normal mucus formation requires cAMP-dependent HCO3- secretion and Ca2+-mediated mucin exocytosis. J Physiol 2013; 591: 4581-4593.
24. Joo NS, Krouse ME, Wu JV, Saenz Y, Jayaraman S, Verkman AS, Wine JJ,. HCO3- transport in relation to mucus secretion from submucosal glands. JOP 2001; 2: 280-284.
25. Ianowski JP1, Choi JY, Wine JJ, Hanrahan JW,. Mucus secretion by single tracheal submucosal glands from normal and cystic fibrosis transmembrane conductance regulator knockout mice. J Physiol 2007; 580: 301-314.
26. Schütte A, Ermund A, Becker-Pauly C, Johansson ME, Rodriguez-Pineiro AM, Bückhed F, Müller S, Lottaz D, Bond JS, Hansson GC,. Microbial-induced meprin β cleavage in MUC2 mucin and a functional CFTR channel are required to release anchored small intestinal mucus. Proc Natl Acad Sci USA 2014; 111: 12396-12401.
27. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW,. Clinical Mechanism of the CFTR potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit 2014; 190: 175-184.
28. Abou Alaiwa MH, Reznikov LR, Gansemer ND, Sheets KA, Horswill AR, Stoltz DA, Zabner J, Welsh MJ,. PH modulates the activity and synergism of the airway surface liquid antimicrobials β-defensin-3 and LL-37. Proc Natl Acad Sci USA 2014; 111: 18703-18708.
29. Kim D, Liao J, Scales N, Palmer ML, Robert R, Fahrenkrug SC, Palmer ML, Robert R, Fahrenkrug SC, O'Grady SM, Hanrahan JW,. CFTR, bicarbonate and host defense. Pediatr Pulmonol 2014; 28: 120-121.
30. Britto CJ, Liu Q, Curran DR, Patham B, Dela Cruz CS, Cohn L,. Short palate, lung, and nasal epithelial clone-1 is a tightly regulated airway sensor in innate and adaptive immunity. Am J Respir Cell Mol Biol 2013; 48: 717-724.
31. Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW,. Rowe SM; GOAL (the G551D observation-AL) investigators of the cystic fibrosis foundation therapeutics development network. pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis 2015; 60: 703-712.
32. De Lisle RC,. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2007; 293: G104.
33. Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K,. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr 2007; 44: 212.
34. Wanke CA, Cronan S, Goss C, Chadee K, Guerrant RL,. Characterization of binding of Escherichia coli strains which are enteropathogens to small-bowel mucin. Infect Immun 1990; 58: 794-800.
35. Lynch SV, Goldfarb KC, Wild YK, Kong W, De Lisle RC, Brodie EL,. Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota. Gut Microbes 2013; 4: 41-47.
36. Duytschaever G, Huys G, Bekaert M, Boulanger L, De Boeck K, Vandamme P,. Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. Appl Environ Microbiol 2011; 77: 8015-8024.
37. Hoffman LR, Pope CE, Hayden HS, Heltshe S, Levy R, McNamara S, Jacobs MA, Rohmer L, Radey M, Ramsey BW, Brittnacher MJ, Borenstein E, Miller SI,. Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with cystic fibrosis. Clin Infect Dis 2014; 58: 396.
38. Heizer WD, Cleaveland CR, Iber FL,. Gastric inactivation of pancreatic supplements. Bull Johns Hopkins Hosp 1965; 116: 261-270.
39. Roy CC, Weber AM, Lepage G, Smith L, Levy E,. Digestive and absorptive phase anomalies associated with the exocrine pancreatic insufficiency of cystic fibrosis. J Pediatr Gastroenterol Nutr 1988; 7: S1-S7.
40. Park HW, Nam JH, Kim JY, Namkung W, Yoon JS, Lee JS, Kim KS, Venglovecz V, Gray MA, Kim KH, Lee MG,. Dynamic regulation of CFTR bicarbonate permeability by [Cl-]i and its role in pancreatic bicarbonate secretion. Gastroenterology 2010; 139: 620-631.
41. Ishiguro H, Yamamoto A, Nakakuki M, Yi L, Ishiguro M, Yamaguchi M, Kondo S, Mochimaru Y,. Physiology and pathophysiology of bicarbonate secretion by pancreatic duct epithelium. Nagoya J Med Sci 2012; 74: 1-18.
42. Kuhn RJ, Eyting S, Henniges F, Potthoff A,. In vitro comparison of physical parameters, enzyme activity, acid resistance, and pH dissolution characteristics of enteric-coated pancreatic enzyme preparations: implications for clinical variability and pharmacy substitution. J Pediatr Pharmacol Ther 2007; 12: 115-128.
43. Choi JY, Muallem D, Kiselyov K, Lee MG, Thomas PJ, Muallem S,. Aberrant CFTR-dependent HCO3-transport in mutations associated with cystic fibrosis. Nature 2001; 410: 94-97.
44. Couper RT, Corey M, Moore DJ, Fisher LJ, Forstner GG, Durie PR,. Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency. Pediatr Res 1992; 32: 179.
45. Ahmed N, Corey M, Forstner G, Zielenski J, Tsui L-C, Ellis L, Tullis E, Durie P,. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 2003; 52: 1159-1164.
46. Youngberg CA, Berardi RR, Howatt WF, Hyneck ML, Amidon GL, Meyer JH, Dressman JB,. Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci 1987; 32: 472-480.
47. Gelfond D, Ma C, Semler J, Borowitz D,. Intestinal pH and gastrointestinal Transit profiles in cystic fibrosis patients measured by wireless motility capsule. Dig Dis Sci 2013; 58: 2275-2281.
48. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW, GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014; 190: 175-184.